Pfizer Inc. Stock
€23.33
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
The Dividend Safe Harbor: 2 Stocks to Watch
It’s been a lackluster year so far for U.S. equities. Year-to-date, the benchmark S&P 500 is slightly in the red, weighed down primarily by a selloff in mega-cap technology. What began as a pause
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report.
Revenue of $17.56 billion topped
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.
In large part, that rebound was
This ETF Is Proof That the Healthcare Rebound Is Real
With well-publicized losses for companies including UnitedHealth Group (NYSE: UNH), Elevance Health (NYSE: ELV), and Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO), the healthcare sector failed
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical
Pfizer Adds to Its Big Bet on Weight Loss Drugs
Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and
5 Healthcare Plays Powering the Sector’s Big Comeback
After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of
TrumpRx Brings Pfizer Into the Green—Is It a Buy?
Pfizer (NYSE: PFE) is no stranger to income investors. The drugmaker, famous for treatments including Lipitor, Viagra, and Zoloft, has now increased its dividend payout for 16 consecutive years
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company (NYSE: LLY), the maker of the wildly popular
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However
Pfizer is Locking in New Growth Through a New Acquisition
In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug
1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
The wash-out from the COVID-19 pandemic has been brutal for any pharmaceutical stock. Pfizer (NYSE: PFE) has been no exception. As a vaccine maker, Pfizer has faced headwinds to growth in the last
2 Healthcare Stocks That Are Too Cheap to Ignore
Some indicators suggest that equity markets are currently overvalued. For instance, the S&P 500 Shiller CAPE ratio is near multi-year highs. In this environment, it pays to look for bargains, stocks
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
A key ratio for dividend investors when looking at dividend stocks is the payout ratio. Since it tells you how large the dividend is with respect to earnings, it can be a good gauge of whether or
2 Top AI Healthcare Stocks to Buy and Hold
Many of the top companies successfully cashing in on artificial intelligence (AI) are in the technology sector. However, AI is having an impact across every industry, and plenty of companies outside
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today
Change is exciting, and it comes with risks. This is why turnaround stocks are so interesting. Right now, Teva Pharmaceutical Industries (NYSE: TEVA) is a turnaround story that may appeal to
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
Eli Lilly's (NYSE: LLY) big problem is its success in the GLP-1 drug space. Its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs grew sales by 99% and 175%, respectively, in 2025.
That's
1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell
If you ask me for a reason I'd buy Pfizer (NYSE: PFE) stock and never sell it, I certainly have one -- because I've already bought into Pfizer, and I have no plans to sell it. Here's a look at why I
Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need
Regencell Bioscience (NASDAQ: RGC), a China-based drugmaker, has been on fire over the past 12 months, with its share price skyrocketing by more than 21,000% as of this writing (that's not a typo)
Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?
Eli Lilly (NYSE: LLY) is growing very quickly right now thanks to Mounjaro and Zepbound, its two GLP-1 drugs, the latter of which is approved for weight loss. Mounjaro's sales rose 99% in 2025, and
This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
Pfizer (NYSE: PFE) is one of the world's largest and most respected pharmaceutical companies. That is an important backdrop for dividend investors to consider as they look at the stock's lofty 6.4%
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
On February 17, 2026, Perceptive Advisors reported a buy of Celcuity (NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on